ADMA Biologics, Inc. Class Action Lawsuit Seeks Recovery for Investors; August 10, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP

A securities fraud class action lawsuit has been filed against ADMA Biologics for allegedly making materially false statements about revenues and internal controls. The lawsuit covers investors who purchased ADMA securities between August 9, 2024 and March 25, 2026. The stock dropped 29.1% after Culper Research published a report alleging channel stuffing and undisclosed related party transactions. The deadline to seek lead plaintiff status is August 10, 2026.